Alaunos Therapeutics
TCRT
124 hedge funds and large institutions have $337M invested in Alaunos Therapeutics in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 18 closing their positions.
16% more capital invested
Capital invested by funds: $290M → $337M (+$47.6M)
3% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.01% less ownership
Funds ownership: 0.27% → 0.27% (-0.01%)
9% less funds holding
Funds holding: 136 → 124 (-12)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
30% less call options, than puts
Call options by funds: $10.9M | Put options by funds: $15.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$46.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.46M |
| 3 |
Morgan Stanley
New York
|
+$2.02M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$1.32M |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.72M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$2.03M |
| 3 |
Citigroup
New York
|
-$1.35M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.15M |
| 5 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$996K |
TCRT Hedge Fund Activity: Q1 2017 in Review
124 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2017, worth a combined $337M — up 16% from $290M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TCRT and 14 opened new positions — a net loss of 4 holders — while 35 trimmed existing stakes and 36 added.
The largest buyer was BlackRock, adding an estimated $46.8M. The largest seller was Susquehanna International Group, cutting an estimated $7.72M.
- 124 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2017, down from 136 in Q4 2016.
- Funds reported $337M of Alaunos Therapeutics stock for Q1 2017, up 16% quarter-over-quarter.
- 14 funds opened new Alaunos Therapeutics positions in Q1 2017 and 18 closed out, a net change of -4 holders.
- The largest Alaunos Therapeutics buyer in Q1 2017 was BlackRock, an estimated $46.8M added.
- The largest Alaunos Therapeutics seller in Q1 2017 was Susquehanna International Group, an estimated $7.72M sold.
Based on aggregated 13F filings for Q1 2017.